The Critical Role of Excipients in GLP-1 Agonist Formulation Design
Webinar
Attend our expert connect session to discover the essential role of excipients in formulation of GLP-1 agonists in both liquid and solid forms, and explore results using a carrier excipient for targeted intestinal drug release of a GLP-1 agonist.
In this expert connect session, you will learn:
- The crucial role excipients play in the formulation of GLP-1 agonists for both liquid and solid dosage forms
- Strategies for designing effective dosage forms, with a focus on solid formulations to improve solubility and achieve targeted drug release using carrier-based excipients
- Insights into the use of granulated buffers in liquid formulations and future outlooks for GLP-1 development
Speakers
Lena Mueller, Ph.D.
Merck
Senior Laboratory Manager
Lena is a pharmacist by training (University of Kiel) with a Ph.D. in organic chemistry and biochemistry (TU Darmstadt). As Head of functional excipients, she leads a team that concentrates on the development and application of functional excipients designed for oral delivery. Solubility enhancement of poorly soluble APIs, continuous manufacturing and the delivery of large molecules are the focus areas of the lab team.
Suruchi Vishwasrao, Ph.D.
Merck
Senior Scientist
Dr. Suruchi Vishwasrao is a Senior Scientist at Formulation and Technology Center, Merck Life science, Mumbai. She was associated with Pharma industries like Emcure, Panacea Biotech, Micro Labs and Academics. She has more than 14 years of experience and has expertise in formulation development of solids, semisolids and NDDS products and has publications in national, international journals as well as in symposia. She is a doctorate in Industrial Pharmacy from A&M Schwartz School of Pharmacy, Long Island University, NY, USA.
Kyung-Min Shin
Merck
Customer Application Consultant
Kyung-min Shin has over 20 years of experience in drug formulation research and marketing/customer applications. He has expertise in various pharmaceutical development areas, including New Chemical Entity (NCE) projects, Incrementally Modified Drugs (IMDs), and Co-development (C&D) projects. Currently, he works as a Customer Application Consultant, where he offers customized solutions for challenges in drug formulation development. He also advises on the selection of pharmaceutical raw materials for both classical and biopharmaceutical industries.
Pharma and biopharma manufacturing
- Small Molecules Analysis and Quality Control
期间:1h
场次 1:往期 May 19, 2026